Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma

Metastatic Renal Cancer Clinical Trial

Official title:
Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma

Status Completed

Clinical Trial Summary

The purpose of this study is the evaluation of dynamic contrast-enhanced CT (Perfusion-CT) for therapeutic response predicition in patients with metastasized renal carcinoma (mRCC) undergoing antiangiogenetic therapy (AAT) with multikinase inhibitors.

In this study patients with mRCC under AAT will be examined with 3 serial Perfusion - CT scans - partially intergrated in their regular staging CT scheme - at baseline (before AAT start), 1 week after AAT as well as 8 weeks after AAT initialization. Thereby selected intrabdomial or intrathoracic metastases will be monitored longitudinally with perfusion CT. Pretreament and post-treament perfusion characteristics of the assessed metastatic lesions will be quantified and correlated with patient outcome.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02086734
Study type	Observational
Source	Ludwig-Maximilians - University of Munich
Contact
Status	Completed
Phase
Start date	April 2012
Completion date	July 2018

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02479490` - PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI	Phase 2
Terminated	`NCT01457131` - Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer	Phase 1
Terminated	`NCT02837757` - Everolimus Modulation of Anti-tumor T CD4 Immune Responses	N/A
Recruiting	`NCT05796973` - Measuring Oncological Value of Exercise and Statin	Phase 3
Recruiting	`NCT03630692` - Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
Terminated	`NCT01160445` - Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer	Phase 2
Recruiting	`NCT04316520` - Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma	N/A
Terminated	`NCT01273181` - MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes	Phase 1/Phase 2